FNR coordinates Luxembourg’s participation in the “COVID-19 Therapeutics Accelerator” initiative

FNR coordinates Luxembourg’s €800,000 participation in the philanthropic initiative COVID-19 Therapeutics Accelerator.

The COVID-19 Therapeutics Accelerator (CTA) is a philanthropic collaboration supporting efforts to research, develop and bring effective treatments against COVID-19 to market quickly and ensure equitable access to such treatments.

Find out more about the Therapeutics Accelerator (CTA)

This initiative is designed to coordinate R&D efforts, remove obstacles to drug development and intensify treatments to fight the pandemic. It is coordinated by three philanthropic organisations, the Bill & Melinda Gates Foundation, Wellcome Trust, and the Mastercard Impact Fund.

Earlier this year, FNR had already committed 800.000 EUR as Luxembourg’s contribution to the Coalition for Epidemic Preparedness (CEPI), a Norway-based global partnership that coordinates the funding of independent research projects to develop vaccines against emerging infectious diseases.

Find out more about CEPI

Through FNR’s participation in these two global initiatives recommended by the WHO, Luxembourg contributes to the worldwide efforts to accelerate the development, production, and equitable access to COVID-19 treatments and vaccines.

Related news

Boosters and vaccinating children: What is the point of view in Luxembourg?

FNR-funded projects during COVID-19: FAQs for grantholders & applicants

Launch of FNR COVID-19 funding instrument

Research Luxembourg: Results second FNR COVID-19 Call

Research Luxembourg: First results of the CON-VINCE study

INTERnational funding possibilities on Sars-CoV-2/ COVID-19

This site uses cookies. By continuing to use this site, you agree to the use of cookies for analytics purposes. Find out more in our Privacy Statement